All In Biotech

NDA 202344 · Radius

Binosto

Alendronate Sodium · Oral

Discontinued

Last checked: Nov 20, 2026Latest source record: Feb 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Mar 12, 2012

Approved uses

1

Original approval plus efficacy supplements

Registered trials

181

59 Phase 3, 7 recruiting

FAERS reports

32,875

27,174 serious, 5,614 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 6, 2026.

BINOSTO is a bisphosphonate indicated for: Treatment of osteoporosis in postmenopausal women ( 1.1 ) Treatment to increase bone mass in men with osteoporosis ( 1.2 ) Limitation of use: Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use ( 1.3 ) 1.1 Treatment of Osteoporosis in Postmenopausal Women BINOSTO effervescent tablet 70 mg is indicated for the treatment of osteoporosis in postmenopausal women. For the treatment of osteoporosis, alendronate sodium increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [See Clinical Studies (14.1) .] 1.2 Treatment to Increase Bone Mass in Men With Osteoporosis BINOSTO is indicated for treatment to increase bone mass in men with osteoporosis [see Clinical Studies (14.2) ] . 1.3 Important Limitations of Use The optimal duration of use has not been determined. The safety and effectiveness of BINOSTO for the treatment of osteoporosis are based on clinical data of four years duration. All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.

Mechanism: Animal studies have indicated the following mode of action. At the cellular level, alendronate shows preferential localization to sites of bone resorption, specifically under osteoclasts. The osteoclasts adhere normally to the bone surface but lack the ruffled border that is indicative of active resorption. Alendronate does not interfere with osteoclast recruitment or attachment, but it does inhibit osteoclast activity. Studies in mice on the localization of radioactive [ 3 H]alendronate in bone showed about 10-fold higher uptake on osteoclast surfaces than on osteoblast surfaces. Bones...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • BINOSTO · ALENDRONATE SODIUM EQ 70MG BASE · TABLET, EFFERVESCENT, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Alendronate" as an intervention, any sponsor and status, largest first.

All 181 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pain6,008
  • fatigue5,923
  • drug ineffective5,675
  • arthralgia5,348
  • rheumatoid arthritis5,157
  • rash4,780
  • abdominal discomfort4,675
  • alopecia4,656
  • femur fracture4,636
  • arthropathy4,418
  • systemic lupus erythematosus4,406
  • pemphigus4,386

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004716
2005692
2006372
2007412
2008679
2009830
20101,051
20111,549
20123,085
20131,575
20141,026
2015872
2016814
2017880
20181,081
20191,136
20201,568
20212,362
20222,636
20231,972
20242,968
20252,864
20261,735

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Binosto (Alendronate Sodium)

2024 spending

$459K

Beneficiaries

283

1,123 claims

Per beneficiary

$1,621

$73.81 per unit

View as table
YearSpending
2020$1,165,135
2021$711,236
2022$699,155
2023$539,470
2024$458,704

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,034 on PubMed

Sponsor: Radius

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.